Gelesis (GLS) Stock Analysis

What Gelesis does

Gelesis Holdings Inc. is a biopharmaceutical company actively marketing products, dedicated to creating biomimetic solutions that target the underlying causes of obesity and chronic gastrointestinal conditions. Among its key offerings is PLENITY, an oral therapeutic designed for weight management that is non-stimulant and does not enter the bloodstream. The company also provides an additional product for individuals who are overweight or obese, and its robust pipeline features potential treatments for non-alcoholic fatty liver disease/non-alcoholic steatohepatitis, type 2 diabetes, and GS500 for Functional Constipation. Established in 2006, Gelesis Holdings Inc. operates from its headquarters in Boston, Massachusetts.

Key metrics

ETFs linked to GLS

Broad-market and Healthcare sector ETFs an investor holding Gelesis is often also exposed to. Open an ETF page to see its actual top holdings.

PortView Portfolio Insights

PortView analyzes how GLS fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Similar companies

Frequently asked questions

What is the ticker symbol for Gelesis?

Gelesis trades under the ticker GLS on NYSE.

Which exchange is GLS listed on?

GLS is listed on NYSE.

What sector does Gelesis operate in?

Gelesis is classified in the Healthcare sector (Biotechnology industry).

How can PortView help analyze GLS in a portfolio?

PortView shows GLS's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.